Reactivation of MEK/ERK signaling is the central mechanism that leads to acquired resistance in BRAFV 600E mutant melanoma, and treatment fails in 50% of melanoma patients (Lito et al., 2012; Rizos et al., 2014). This evidence concerns the gene MAP2K7 and melanoma.